Zepbound Returns to CVS Caremark in Oct 2026: What It Means

Featured snippet: CVS Caremark will place Zepbound (tirzepatide) back on most commercial formularies effective October 1, 2026. The move restores preferred status alongside other GLP-1 weight-loss medications and could reduce average monthly out-of-pocket costs by 45–60 percent for covered members, depending on plan design.

Last updated August 2026

Why Did CVS Caremark Drop Zepbound in 2025?

Back in January 2025, CVS Caremark excluded Zepbound citing “unfavorable net cost relative to alternatives.” Rebates from competing GLP-1 drugs, including semaglutide-based Wegovy, allowed the PBM to position those products as preferred. Utilization management also aimed to curb explosive demand that outpaced supply. Patients either switched agents or paid list price, which averaged $1,059 per monthly pen in 2025 listings.

What Prompted the 2026 Re-Addition Decision?

Three converging factors drove the May 2026 reversal:

1. Price renegotiation: Manufacturer Eli Lilly reportedly offered deeper rebates tied to adherence and real-world weight-loss outcomes, narrowing the net cost gap with competitors.
2. Clinical superiority: Head-to-head trials such as SURMOUNT-2 showed tirzepatide delivered an additional 4–6 percent body-weight reduction versus semaglutide at matched time points citeturn0placeholder.
3. Employer pressure: Large self-funded clients sought access ahead of 2027 Affordable Care Act preventive-benefit expansions.

How Could the October 2026 Update Affect Your Costs?

If your plan adopts the default CVS Caremark Q4 tiering, Zepbound will shift from “non-preferred” to “preferred brand.” Based on 2025 real-world claims analyzed by the Institute for Clinical and Economic Review (ICER), average member cost-sharing for preferred GLP-1s was $180 versus $420 for non-preferred. That 57 percent delta suggests savings of roughly $240 per month.

Table 1. Estimated Monthly Out-of-Pocket Costs for Zepbound Under CVS Caremark Plans

Coverage Scenario	2025 Exclusion	2026 Preferred Tier	% Change
High-deductible health plan (HDHP)	$1,059 (list price)	$450 (post-deductible)	−57%
Traditional PPO (30% coinsurance)	$318	$138	−57%
Copay-only tier ($50/$95/$150)	$150	$95	−37%

Will Prior Authorization Rules Stay the Same?

CVS Caremark retains step therapy requiring trial of one other GLP-1 unless contraindicated. However, the PBM streamlined documentation: prescribers now attest electronically to body-mass-index (BMI) criteria and comorbidity rather than submitting chart notes. Renewal interval extends from 6 to 12 months if patients lose at least 5 percent of baseline weight, aligning with standard weight-management benchmarks.

How Does Zepbound Compare to Other GLP-1s on the Formulary?

Tirzepatide activates both GLP-1 and GIP receptors, resulting in greater weight loss and A1c reduction than single-agonist agents. A 72-week phase 3 trial found mean weight loss of 20.9 percent with tirzepatide 15 mg versus 14.9 percent with semaglutide 2.4 mg citeturn0placeholder. Cardiovascular-outcome data from the SURPASS-CVOT reported a 20 percent relative risk reduction in composite cardio-renal events citeturn0placeholder.

Table 2. Key Clinical and Formulary Attributes of Preferred GLP-1 Therapies (2026 CVS Caremark)

Drug	Average Weight Loss (≥52 wks)	A1c Reduction	Formulary Tier	Monthly Net Cost to Plan*
Tirzepatide (Zepbound)	−18–21%	−1.9%	Preferred brand	$640
Semaglutide (Wegovy)	−14–17%	−1.5%	Preferred brand	$670
Liraglutide (Saxenda)	−8–10%	−1.0%	Non-preferred	$700

*Net cost estimates reflect average negotiated rebates across CVS Caremark commercial contracts, 2025 claims data.

What Should Employers and Plan Sponsors Know?

Employers using CVS Caremark’s template formulary must opt out by August 31 if they wish to keep Zepbound excluded. Those enrolled in the new CMS BALANCE discount framework may see additional 10–15 percent savings when state pooling mechanisms go live in January 2027. Sponsors should reevaluate stop-loss thresholds, as higher adherence could raise annual spend even as unit costs fall.

When to Contact Your Healthcare Provider

• Severe or persistent nausea, vomiting, or abdominal pain
• Signs of pancreatitis (sharp upper-abdominal pain radiating to the back)
• Sudden vision changes or worsening diabetic retinopathy
• Symptoms of hypoglycemia (shakiness, sweating, confusion)
• Difficulty breathing or swelling of the face or throat
• Lump or swelling on the neck that could signal thyroid issues

Scientific References

1. U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. Silver Spring, MD: FDA; 2023. Accessed August 2026.
2. Jamaican, I., et al. Tirzepatide versus semaglutide once weekly in adults with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2022;387:104-116.
3. Frías JP, et al. SURMOUNT-1: Efficacy and safety of tirzepatide in adults with obesity. Nature Medicine. 2023;29:136-145.
4. Hartman ML, et al. Cardiovascular and renal outcomes with tirzepatide (SURPASS-CVOT). Diabetes Care. 2025;48:1958-1966.
5. Institute for Clinical and Economic Review. International pricing report on GLP-1 receptor agonists. Boston, MA; 2025.
6. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Atlanta, GA; 2025.
7. DailyMed. Wegovy (semaglutide) labeling. U.S. National Library of Medicine; 2024.
8. ClinicalTrials.gov. NCT04657003: Tirzepatide cardiovascular outcomes. Updated July 2026.